Patents by Inventor David Philip Rooker
David Philip Rooker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059691Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in medicine; and methods of treating patients with such compounds; wherein A, W, R5, n, Z, X, Y and B are as defined herein. The present invention also relates to compounds useful as synthetic intermediates of compounds of formula (I).Type: ApplicationFiled: December 1, 2021Publication date: February 22, 2024Inventors: Mitchell Lewis CHILDS, Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, William Jack GREVES, Simon Teanby HODGSON, Alessandro MAZZACANI, Carl Leslie NORTH, Alicja Stela OBARA, Michael Bryan ROE, David Philip ROOKER, Michael John STOCKS, Louise Michelle BIRCH, Mark PICHOWICZ, Rachael PITTAWAY, Alun John SMITH, Adam Eric THROUP, Joseph William WRIGGLESWORTH, Xuezheng YANG, David Edward CLARK
-
Publication number: 20220298138Abstract: The present invention provides compounds of formula (I): Formula (I) compositions comprising such compounds; the use of such compounds in therapy; and methods of treating patients with such compounds; wherein A, Y, n, R1, R2A, R2B, R3 and *1 are as defined herein.Type: ApplicationFiled: August 21, 2019Publication date: September 22, 2022Inventors: Rebecca Louise DAVIE, Hannah Joy EDWARDS, David Michael EVANS, Simon Teanby HODGSON, Sally Louise MARSH, Alessandro MAZZACANI, David Philip ROOKER, Michael John STOCKS, Andrew Peter CRIDLAND, Emanuela GANCIA, Julie Nicole HAMBLIN, Paul Stuart HINCHLIFFE, Stefano LEVANTO, Terence Aaron PANCHAL, Iain Robert MILLER
-
Publication number: 20220002275Abstract: The present invention provides a selection of compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Type: ApplicationFiled: September 21, 2021Publication date: January 6, 2022Inventors: Rebecca Louise Davie, Hannah Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Stephen John Pethen, David Philip Rooker
-
Patent number: 11180484Abstract: The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.Type: GrantFiled: May 31, 2017Date of Patent: November 23, 2021Assignee: KalVista Pharmaceuticals LimitedInventors: Rebecca Louise Davie, Hanna Joy Edwards, David Michael Evans, Simon Teanby Hodgson, Stephen John Pethen, David Philip Rooker
-
Patent number: 9738641Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, B, W, X and Y are as defined herein.Type: GrantFiled: August 14, 2014Date of Patent: August 22, 2017Assignee: Kalvista Pharmaceuticals LimitedInventors: Hannah Joy Edwards, David Michael Evans, Rebecca Louise Davie, David Philip Rooker, Steven John Hewison
-
Publication number: 20160185773Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein A, B, W, X and Y are as defined herein.Type: ApplicationFiled: August 14, 2014Publication date: June 30, 2016Inventors: Hannah Joy EDWARDS, David Michael EVANS, Rebecca Louise DAVIE, David Philip ROOKER, Steven John HEWISON
-
Patent number: 9234000Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.Type: GrantFiled: April 15, 2015Date of Patent: January 12, 2016Assignee: Kalvista Pharmaceuticals LimitedInventors: David Michael Evans, Rebecca Louise Davie, Hannah Joy Edwards, David Philip Rooker
-
Publication number: 20150225450Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.Type: ApplicationFiled: April 15, 2015Publication date: August 13, 2015Inventors: DAVID MICHAEL EVANS, REBECCA LOUISE DAVIE, HANNAH JOY EDWARDS, DAVID PHILIP ROOKER
-
Patent number: 9051249Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.Type: GrantFiled: July 6, 2012Date of Patent: June 9, 2015Assignee: KalVista Pharmaceuticals LimitedInventors: David Michael Evans, Rebecca Louise Davie, Hannah Joy Edwards, David Philip Rooker
-
Publication number: 20140213611Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R1 to R9 are as defined herein.Type: ApplicationFiled: July 6, 2012Publication date: July 31, 2014Applicant: KalVista Pharmaceuticals LimitedInventors: David Michael Evans, Rebecca Louise Davie, Hannah Joy Edwards, David Philip Rooker
-
Publication number: 20100076015Abstract: The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients with such compounds; wherein R1-R11 are as defined herein.Type: ApplicationFiled: April 28, 2009Publication date: March 25, 2010Applicant: VANTIA LIMITEDInventors: David Michael Evans, Christine Elizabeth Allan, John Horton, David Philip Rooker
-
Publication number: 20080255109Abstract: Compounds according to general formula 1, wherein A1-A3 are selected from A5 and A6 where A5 is either ?CR13— or ?N— and A6 is —NR14—, —O— or —S—; A4 is either a covalent bond or A5, provided that when A4 is a covalent bond one of A1-A3 must be A6 and the other two must be A5 and when A4 is A5 then all of A1-A3 must be A5; R1 is selected from H, NHY? and COY2, in which case R2 is H, or R1 and R2 may both be methyl or together represent ?O; R3, R4 and R5 are each independently selected from H and lower alkyl groups; R6, R7, R8, R9, R10, R11 and R12 are each independently selected from H, lower alkyl groups, NH2, halogens (F, Cl and Br) O-alkyl, CH2NM2 and CF3; R13 is selected from H, F, Cl, Br, NO2, NH2, OH, Me, Et, OMe, NMe2 and CF3; R14 is selected from H, methyl and ethyl; W is selected from ?CH— and ?N—; X is selected from CH2, O, S, SO2, NH and N-lower alkyl; Y1 is selected from CO-lower alkyl, CO(CH2)bY3, CO(CH2)bCOY3 and CO(CH2)bNHCOY3, where b is 1-3; Y2 is selected from OR15, NR16R17 and NH(CH2)cCOY3,Type: ApplicationFiled: April 28, 2008Publication date: October 16, 2008Inventors: Michael Bryan Roe, Andrzej Roman Batt, David Michael Evans, Gary Robert William Pitt, David Philip Rooker
-
Patent number: 7365065Abstract: Compounds according to general formula 1, wherein A1-A3 are selected from A5 and A6 where A5 is either ?CR13— or ?N— and A6 is —NR14—, —O— or —S—; A4 is either a covalent bond or A5, provided that when A4 is a covalent bond one of A1-A3 must be A6 and the other two must be A5 and when A4 is A5 then all of A1-A3 must be A5; R1 is selected from H, NHY? and COY2, in which case R2 is H, or R1 and R2 may both be methyl or together represent ?O; R3, R4 and R5 are each independently selected from H and lower alkyl groups; R6, R7, R8, R9, R10, R11 and R12 are each independently selected from H, lower alkyl groups, NH2, halogens (F, Cl and Br) O-alkyl, CH2NM2 and CF3; R13 is selected from H, F, Cl Br, NO2, NH2, OH, Me, Et, OMe, NMe2 and CF3; R14 is selected from H, methyl and ethyl; W is selected from ?CH— and ?N—; X is selected from CH2, O, S, SO2, NH and N lower alkyl; Y1 is selected from CO-lower alkyl, CO(CH2)bY3, CO(CH2)bCOY3 and CO(CH)NHCOY3, where b is 1-3; Y2 is selected from OR15, NR16R17 and NH(CH2)CCOY3, whType: GrantFiled: March 12, 2003Date of Patent: April 29, 2008Assignee: Ferring B.V.Inventors: Michael Bryan Roe, Andrzej Roman Batt, David Michael Evans, Gary Robert William Pitt, David Philip Rooker
-
Publication number: 20040235753Abstract: Compounds according to general formula 1, wherein G1 is NR6R7 or a group according to general formula 3 and G2 NR24R25 or a fused polycyclic group are novel. They are selective and potent oxytocin agonists. Pharmaceutical compositions of such compounds are useful in the treatment of, inter alia, erectile dysfunction.Type: ApplicationFiled: December 24, 2003Publication date: November 25, 2004Inventors: Gray Robert William Pitt, Michael Bryan Roe, David Philip Rooker